A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims ...

NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

A scientist diagnosed with an ultra-rare form of ALS linked to a CHCHD10 gene mutation is now enrolled in a one-of-a-kind ...

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...

─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical ...

After a period of clinical recalibration, the ALS and FTD field is regaining momentum, driven by a deeper biological understanding, more refined translational strategies, and continued industry ...

Pennington Biomedical’s Dr. Jeff Keller and Dr. Aron Culotta of Tulane to lead collaboration of AI researchers, neuroscientist and drug developers Answer ALS is proud to announce the launch of a ...

Add Yahoo as a preferred source to see more of our stories on Google. Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com (MAXIMUM ...